GRI Bio Reports Positive Phase 2a Trial Results

GRI Bio ( (GRI) ) has issued an update.

GRI Bio, Inc. has announced positive topline results from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The trial met its primary and certain secondary endpoints, demonstrating that GRI-0621 was well tolerated over a 12-week period and showed potential anti-fibrotic effects, with improvements in serum biomarkers and Forced Vital Capacity (FVC) in treated subjects. No serious adverse events were observed, and the findings suggest a promising impact on fibrosis resolution and lung tissue repair, potentially enhancing GRI Bio’s position in the IPF treatment market.

The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.

Spark’s Take on GRI Stock

According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.

GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.

To see Spark’s full report on GRI stock, click here.

More about GRI Bio

Average Trading Volume: 1,213,734

Technical Sentiment Signal: Sell

Current Market Cap: $6.73M

For detailed information about GRI stock, go to TipRanks’ Stock Analysis page.